By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Opsona Therapeutics Ltd. 

The O'Reilly Institute
Trinity College Dublin
Dublin    2  Ireland
Phone: n/a Fax: 353-1-679-8039


SEARCH JOBS


Industry
Pharmaceutical






Company News
Opsona Therapeutics Ltd. Patent Issued In USA Covering An Antibody Directed Against Toll-Like Receptor-2 (TLR-2) And The Use And Development Thereof 2/23/2015 10:19:31 AM
Opsona Therapeutics Ltd. Patent Issued In US And EU Covering The Opsona-Developed Antibody OPN-305, Which Is Directed Against Toll-Like Receptor-2 (TLR-2) And The Use And Development Thereof 2/20/2015 12:54:08 PM
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015 1:27:04 PM
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015 9:31:12 AM
Opsona Therapeutics Ltd. Raises an Additional $4 Million Series C From Omnes Capital 10/2/2013 7:10:30 AM
Opsona Therapeutics Ltd. Initiates a Phase II Study With OPN-305, a First-in Class Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function 5/7/2013 11:19:59 AM
Opsona Therapeutics Ltd. Raises $43 Million to Develop Lead Product 4/29/2013 6:56:26 AM
Opsona Therapeutics Ltd. Announces the Issuance of New Patent From the European Patent Office (EPO) Covering the Development and Use of an Antibody Directed Against Toll-like Receptor TLR-2 4/17/2012 10:24:23 AM
Opsona Therapeutics Ltd. Adds 3.3 Million Euro to Series B 5/20/2009 8:13:04 AM
Galapagos NV (GLPG.BR) And Opsona Therapeutics Ltd. Initiate Drug Discovery Collaboration 4/21/2009 12:11:23 PM
12
//-->